Conferences and Symposia
Permanent URI for this communityhttp://repository.kln.ac.lk/handle/123456789/10376
Conference papers presented at Conferences and Symposia organized by the Faculty of Medicine are collected under this subcommunity
Browse
2 results
Search Results
Item Role of Cancer antigen 15.3 in the pre-operative assessment of primary breast cancer(Faculty of Medicine, University of Kelaniya, Sri Lanka, 2016) Peiris, H.H.; Mudduwa, L.K.B.; Wijeratne, W.M.D.G.B.; Liyanage, T.G.; Liyanage, N.C.; Gunasekara, S.N.; Kaushalya, M.H.A.BACKGROUND: Cancer antigen (CA) 15.3 is the most commonly used tumour marker in predicting recurrence of breast cancer. The role of pre-operative CA 15.3 in the assessment of breast cancer has not been substantiated yet. OBJECTIVE: To determine the role of CA 15.3 in the pre-operative assessment of breast cancer patients METHODS: All patients who were diagnosed of primary breast cancer and underwent surgery at a tertiary-care hospital from April 2014 to October 2015 were enrolled. Serum level of CA 15.3 was assessed on a pre-operative blood sample by ELISA and ≥30 U/ml was considered as the cut off as defined by the manufacturer’s literature. The association of CA 15.3 levels with the clinico-pathological parameters was analyzed with chi-square test. RESULTS: Of the 150 patients (mean age 56.83 [SD=13.39] years) enrolled, majority (85.6%) had grade 2/3 tumours with lymph node metastasis (58.2%) at the time of presentation. None had distant metastasis. Elevated pre-operative serum level of CA 15.3 was detected in 34% of patients who had more estrogen receptor negative(43.13%), progesterone receptor negative (50.98%) and triple negative(29.1%) tumours compared to those without elevated pre-operative CA 15.3 (p=0.017,0.036 and 0.001 respectively). There was no association with other clinico-pathological features. CONCLUSIONS: Pre-operative serum level of CA15.3 is elevated only in one third of breast cancer patients. Elevated pre-operative CA 15.3 has a prognostic value as it is elevated mostly in the hormone receptor negative and triple negative breast cancers predicting a poor prognosis.Item Cancer antigen 15-3 and the grade of the breast carcinoma in newly diagnosed patients(Faculty of Medicine, University of Kelaniya, Sri Lanka, 2016) Akalanka, H.M.K.; Ekanayake, S.; Samarasinghe, K.BACKGROUND: Cancer antigen 15-3 (CA15-3) is a breast tumor marker of clinical utility. However, the utility of measuring CA15-3 in patients with breast cancer (BC) remains controversial. OBJECTIVES: To assess CA15-3 concentrations of newly diagnosed BC patients and to compare those with concentrations of apparently healthy females and within the different the grades of the carcinoma. METHODS: CA15-3 concentration of newly diagnosed BC patients (n=155) and apparently healthy age matched females (n=35) was assessed using enzyme immunoassay sandwich method with a final fluorescent detection using mini vidas immuno analyser. Nottingham grade of the carcinoma of each BC patient was recorded from the histopathology records. RESULTS: The median levels of CA15-3 of the BC patients and apparently healthy women in the study sample was 14.45 (IQR: 10.17) U/mL and 14.19 (IQR: 7.09) U/mL respectively. CA15-3 concentrations were not significantly different among BC and healthy women (p>0.05). Only 11% of women with BC had elevated CA15-3 concentrations above the reference range (30 U/mL). The BC patients were classified as Nottingham grade I (13.4%), II (47.8%) and III (38%). CA15-3. Concentrations (median and IQR) within each grade were 15.24 (6.62), 13.06 (11.56) and 17.52 (13.69) respectively. CA15-3 concentrations were not significantly different according to the grade (p>0.05). CONCLUSIONS: CA 15-3 concentrations of newly diagnosed breast cancer patients were not significantly different when compared with apparently healthy women and according to the Nottingham grading.